Page 10 - Ancer Prostate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

A new NCCN survey found that most centers are experiencing shortages of carboplatin and cisplatin. The NCCN has called for strategies to address these drug shortages.

Second-generation antiandrogens for prostate cancer carry a substantial risk of cognitive problems and fatigue, and they increase the risk of falls by 87%, warn researchers.

The prevalence of 'actionable' genes is similar across genomes of men from African, European, Asian, or mixed ancestry, suggesting that genomics alone can't account for racial disparities in outcomes.

The risk for interstitial lung disease in patients with PsA during the first 5 years was five times higher than for the general population, and the risk was not modified by methotrexate use.

The new indication adds to the PARP inhibitor's previous approvals for HRR-mutated metastatic castration-resistant prostate cancer as well as for ovarian, breast, and pancreatic cancer indications.